西洛他唑与外周动脉疾病血运重建后主要肢体及心血管事件风险
结果显示,西洛他唑使用与主要不良肢体事件(MALE)、主要不良心血管事件(MACE)及全因死亡风险降低相关,大出血未见显著差异但两组绝对发生率均较高。
要点
- 西洛他唑与血运重建后MALE风险显著降低相关(SHR 0.50,95%CI 0.46-0.53)。
- MACE与全因死亡风险亦降低(HR分别为0.84与0.91),大出血无显著增加。
- 未联用其他抗血小板药者肢体获益更明显,仍需随机对照试验验证。
核心结论
- PAD血运重建后使用西洛他唑与肢体事件、心血管事件及全因死亡风险降低相关,且未增加大出血,但两组大出血绝对发生率均较高。
研究设计与样本
- 回顾性、全国性、倾向评分匹配队列研究,使用台湾全民健康保险研究数据库。
- 纳入2010-2023年因PAD接受下肢血运重建、随访至2024年的患者,排除既往使用西洛他唑者。
- 比较反映西洛他唑联合或不联合背景抗血栓治疗的使用情况。
主要发现
- MALE:78.7 vs. 154.0 events/1 000 person-years,SHR 0.50(95%CI 0.46-0.53)。
- MACE:97.9 vs. 117.1 events/1 000 person-years,HR 0.84(95%CI 0.79-0.89)。
- 全因死亡:116.0 vs. 127.6 events/1 000 person-years,HR 0.91(95%CI 0.86-0.96)。
- 大出血:SHR 0.90(95%CI 0.81-1.00),绝对发生率12.1% vs. 13.1%。
- 亚组分析显示未使用其他抗血小板药的患者肢体获益更大。
关键数值与推荐
- MALE的SHR 0.50(95%CI 0.46-0.53),MACE的HR 0.84(95%CI 0.79-0.89)。
- 全因死亡HR 0.91(95%CI 0.86-0.96),大出血SHR 0.90(95%CI 0.81-1.00)。
- 大出血绝对发生率12.1% vs. 13.1%。
临床怎么用
- 对PAD下肢血运重建后患者,可考虑西洛他唑以降低肢体与心血管事件风险,尤其未联用其他抗血小板药者。
- 用药时需关注大出血风险,因两组绝对发生率均较高。
- 研究结果来自观察性数据,临床决策应结合个体出血风险与随机试验证据。
局限性
- 为回顾性观察性研究,存在残余混杂可能。
- 比较反映西洛他唑联合或不联合背景抗血栓治疗,非随机对照。
- 作者指出需开展以心血管事件为终点的随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with peripheral artery disease (PAD) remain at high risk of major adverse limb events (MALE) and cardiovascular events (MACE) after revascularisation. Cilostazol, a phosphodiesterase-3 inhibitor with antiplatelet and antiproliferative effects, reduces re-stenosis but its real world impact on clinical outcomes is uncertain. This retrospective, nationwide, propensity score matched cohort study evaluated the effectiveness and safety of cilostazol on MALE, MACE, and all cause mortality after lower limb revascularisation for PAD. METHODS: Using the Taiwan National Health Insurance Research Database, patients who underwent lower limb revascularisation for PAD from 2010 - 2023, with follow up through 2024 were identified. Patients with prior cilostazol use were excluded. 1:1 propensity score matching (n = 5 464 per group) adjusted for baseline differences. Cox regression and Fine-Gray competing risk models were used to evaluate outcomes. The comparison reflects cilostazol used with or without background antithrombotic therapy. RESULTS: Cilostazol use was associated with significantly lower risks of MALE (78.7 vs. 154.0 events/1 000 person-years; subdistribution hazard ratio [SHR] 0.50; 95% confidence interval [CI] 0.46 - 0.53) and MACE (97.9 vs. 117.1 events/1 000 person-years; hazard ratio [HR] 0.84; 95% CI 0.79 - 0.89). All cause mortality was also reduced (116.0 vs. 127.6 events/1 000 person-years; HR 0.91; 95% CI 0.86 - 0.96). Major bleeding did not differ significantly between groups (SHR 0.90; 95% CI 0.81 - 1.00), although the absolute rate was high in both groups (12.1% vs. 13.1%). Subgroup analysis showed greater limb benefit in patients not on other antiplatelet agents. CONCLUSION: Cilostazol after PAD revascularisation was associated with lower risks of limb and cardiovascular events and mortality. These effects were observed without any increase in the rate of major bleeding, although this rate was high in both groups. Randomised trials focused on cardiovascular events are needed.
引用
- Shu-Han Lin D, Wu HP, Chung WJ, et al. Cilostazol and Risk of Major Adverse Limb and Cardiovascular Events after Revascularisation for Peripheral Artery Disease. Eur J Vasc Endovasc Surg. 2026. PMID: 42887644. doi:10.1016/j.ejvs.2026.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。